Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Universal Influenza Vaccines (cH8/1N1 LAIV and cH5/1N1 IIV) in Healthy Adults
NCT03300050Phase 1Completed
- Sponsor
- PATH
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cH8/1N1 LAIV, cH5/1N1 and D-SUIV cH8/1N1 in influenza (5 arms), sponsored by PATH. Primary endpoints: Number of Participants With Solicited Local Reactions, Number of Participants With Solicited General Reactions and 3 more. Started Oct 2017; status: completed.
02
Drugs
cH8/1N1 LAIVcH5/1N1D-SUIV cH8/1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03300050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300050.